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Abstract
Objectives—The purpose of this review is to identify and analyze published studies that have
evaluated disparities for opportunistic infection (OI) prophylaxis between Blacks and Whites with
HIV/AIDS in the United States.
Methods—The authors conducted a web-based search of MEDLINE (1950 to 2009) to identify
original research articles evaluating the use of OI prophylaxis between Blacks and Whites with
HIV/AIDS. The search was conducted utilizing the following MeSH headings and search terms
alone and in combination: HIV, AIDS, Black, race, ethnicity, disparities, differences, access,
opportunistic infection, and prophylaxis. The search was then expanded to include any relevant
articles from the referenced citations of the articles that were retrieved from the initial search
strategy. Of the 29 articles retrieved from the literature search, 19 articles were excluded.
Results—Ten publications met inclusion criteria, collectively published between 1991 and 2005.
The collective time periods of these studies spanned from 1987 to 2001. Four studies identified a
race-based disparity in that Blacks were less likely than Whites to use OI prophylaxis, whereas
five studies failed to identify such a relationship between race and OI prophylaxis. One study
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identified disparities for Mycobacterium avium complex (MAC) prophylaxis, but not for
Pneumocystis jiroveci pneumonia (PCP) prophylaxis.
Conclusions—The evidence regarding race-based disparities in opportunistic infection
prophylaxis is inconclusive. Additional research is warranted to explore potential race-based
disparities in OI prophylaxis.
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Introduction
Opportunistic infections (OIs) are a major source of morbidity and mortality among patients
with Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome
(AIDS); thus, appropriate antimicrobial prophylaxis against these infections is critical for
survival.1,2 Guidelines for the prevention of Pneumocystis carinii pneumonia (also referred
to as P. jiroveci, or PCP) have been in place since 1989.3 Since then, the Centers for Disease
Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV
Medicine Association of the Infectious Diseases Society of America have all implemented
guidelines to effectively prevent and reduce OIs in HIV-infected persons.4
With the use of appropriate OI prophylaxis and potent highly active antiretroviral therapy
(HAART), there has been a remarkable decline in the incidence of OIs for the HIV/AIDS
population overall.5-7 For instance, the efficacy of trimethoprim-sulfamethoxazole (TMP-
SMX) for preventing PCP was first demonstrated in a small, randomized, controlled trial
among HIV patients diagnosed with Kaposi sarcoma; no patient using prophylaxis in the
study developed PCP infection.8 Over the years, several other agents have been incorporated
as recommended and/or alternative therapies for preventing PCP including pentamidine,
dapsone, atovaquone, and pyrimethamine plus leucovorin.4 PCP primary prophylaxis is
indicated among HIV-infected individuals with CD4+ <200, or who have a history of
oropharyngeal candidiasis. Primary prophylaxis is also available for Mycobacterium avium
complex (MAC) and may include azithromycin, clarithromycin, or rifabutin, and is
indicated for individuals with a CD4+ <50. Guideline recommendations have also
incorporated preventative measures for a number of other OIs and are outlined in Table 1.4
While effective prophylaxis has been available for over two decades, it is questionable
whether all populations, including the Black U.S. population, use timely prophylaxis for
OIs. Blacks represent a small proportion (13%) of the U.S. population, yet they account for
48% of all HIV/AIDS diagnoses and 49% of new AIDS diagnoses.9,10 Many individuals
unaware that they are infected only seek care after they display symptoms of an underlying
OI.11-13
Blacks are more likely to be “late-presenters” than Whites.11 These late presenters may not
receive the full clinical benefits of therapy as they are at advanced stages of
immunosuppression and are risk for suffering poorer outcomes, including higher rates of
mortality.14-16 Furthermore, many prophylactic therapies were evaluated in clinical trials
with a limited number of Black patients; therefore, the safety and efficacy of these therapies
for the Black HIV/AIDS population is largely unknown.17,18 The present study sought to: 1)
evaluate the available literature pertaining to racial disparities in OI prophylaxis, 2)
determine the extent to which preventative measures reach Blacks and Whites with HIV/
AIDS, and 3) propose areas for future research for OI prophylaxis disparities.
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A web-based search of MEDLINE (January 1, 1950 to December 31, 2009) was performed
to identify articles published in the English language that evaluated the use of OI
prophylaxis between Blacks and Whites with HIV/AIDS. For the purposes of this review, OI
prophylaxis “use” refers to both prescription of OI prophylaxis and receipt of OI
prophylaxis. The search was conducted utilizing the following search terms alone and in
combination: “HIV,” “AIDS,” “Black,” “race,” “ethnicity,” “disparities,” “differences,”
“access,” “opportunistic infection,” and “prophylaxis.” The search was then expanded to
include any relevant articles from the referenced citations of the articles that were retrieved
from the initial search strategy.
Articles were included if they met the following criteria: evaluated OI prophylaxis use,
presented original data, included only U.S. study populations, analyzed Black race/ethnicity
race-based disparities for OI prophylaxis, studied non-pediatric populations, and involved
prophylaxis pertaining to HIV infection. All abstracts were initially screened for the above
criteria.
Results
We summarize the findings of the ten publications that met inclusion criteria, collectively
published between 1991 and 2005. The study periods spanned from 1987 to 2001. A
flowchart of the manuscript selection process is illustrated in Figure 1 and an overview of
the individual study results is presented in Table 2. Of the 29 articles retrieved from the
literature search, 19 articles were excluded because they failed to meet inclusion criteria
outlined in the methods; 12 did not evaluate racial disparities in OI prophylaxis, three did
not present original data, two encompassed pediatric populations, one encompassed non-
U.S. study populations and the last article did not involve OI prophylaxis pertaining to an
HIV population.
Studies that Documented Black-White Disparities for OI Prophylaxis
The following studies detected a race-based disparity, in that Blacks were less likely to use
OI prophylaxis as compared to Whites. From 1993 to 1995, Solomon et al. recruited women
with HIV or at risk for HIV infection from clinical care centers of a prospective cohort, the
HIV Epidemiology Research Study (HERS).19 Women completed interview-administered
questionnaires and were instructed to describe their utilization of HIV health services,
including use of HIV-related medications. Black women were less likely to report current
PCP prophylaxis use compared to White women, (adjusted odds ratio, 0.34; 95% CI,
0.13-0.85). Black women were also less likely to report current prophylaxis for other OIs
compared to White women, (adjusted odds ratio, 0.50; 95% CI, 0.30-0.83). Siegel et al.
sought to evaluate disparities in HIV care by interviewing HIV-positive women in New
York City between 1994 and 1995.20 Blacks reported lower use of aerosolized pentamidine
than Whites (0% vs. 13%; p<0.05) but no differences were noted for TMP-SMX or dapsone.
Regression analyses were not conducted in this study so the authors were unable to control
for other variables that could have influenced their study results. Sackoff et al.
retrospectively assessed trends in HIV-related medications for patients seen in New York
City clinics from 1995 to 1997.21 Race was not associated with PCP prophylaxis; however,
Blacks were less likely to use MAC prophylaxis compared to Whites, (adjusted odds ratio
0.08; 95% CI, 0.01-0.52). Shapiro et al. prospectively evaluated variations in medication
utilization within the HIV Cost and Services Utilization Study (HCSUS) from 1996-1998.22
Per multivariable analysis, Blacks had a higher likelihood for not using PCP prophylaxis
within the six months prior to the initial interview compared to Whites, (adjusted odds ratio,
1.54; 95% CI, 1.03-2.29). Lastly, in 1996, Jeffe et al. interviewed HIV-positive patients
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regarding their current use of HIV medications.23 Of all participants, fewer Blacks
recognized any of the PCP prophylactic medications compared to Whites (65% vs. 88%;
p<0.001).
Studies that Did Not Document Black-White Disparities for OI Prophylaxis
The following studies did not detect an association between race and OI prophylaxis.
Easterbrook et al. prospectively evaluated racial differences in PCP prophylaxis among
HIV/AIDS individuals in metropolitan centers across the United States from 1987 to 1988.24
While Blacks were less likely to use PCP prophylaxis at time of study enrollment and at
follow-up, the authors concluded that race did not have a significant effect on OI
prophylaxis use at follow-up after adjusting for differences in prophylaxis use across the
different study sites. Moore et al. prospectively collected data from medical records and
patient interviews for HIV/AIDS patients seeking care at the Johns Hopkins Hospital AIDS
Service HIV clinic between 1990 and 1992.25 No racial differences were noted for PCP
prophylaxis use as patients continued in care (regression analyses were not presented in the
study results). Similar to that of the Moore et al. study, Smith et al. collected data via a
series of patient interviews and medical chart abstractions within the AIDS Costs and
Services Utilization Survey (ACSUS) from 1991 and 1992.26 The adjusted odds ratio for
Blacks (vs. Whites) for the likelihood of PCP prophylaxis use among all participants was
0.87 (95% CI, 0.70-1.07). For those with a CD4+ <200 or with a history PCP, the adjusted
odds ratio was 0.83 (95% CI, 0.65-1.06). From 1996 to 1997, Asch et al. sought to
characterize the influence of demographic factors on rates of primary prophylaxis for both
PCP and MAC in the nationally representative HCSUS.27 The investigators concluded that
Blacks, compared to Whites, were not disadvantaged regarding PCP prophylaxis at baseline
(adjusted odds ratio, 0.93, 95% CI 0.47-1.9). The adjusted odds ratio for PCP prophylaxis at
follow-up was mistakenly not reported; nevertheless, the 95% CI was 0.54-2.4, implying a
lack of statistical significance. Blacks were less likely than Whites to use MAC prophylaxis
at baseline, (adjusted odds ratio, 0.35; 95% CI, 0.20-0.59). This race-based disparity no
longer existed for Blacks at study follow-up, (adjusted odds ratio, 0.86; 95% CI, 0.37-2.0).
The most recent findings are from a cross-sectional, observational study by Gebo et al. in
2001, which sought to identify demographic factors that were associated with lack of OI
prophylaxis within the HIV Research Network (HIVRN).28 Blacks were equally as likely as
Whites to use PCP prophylaxis, (adjusted odds ratio without outpatient utilization, 0.95;
95% CI, 0.68-1.32; adjusted odds ratio with outpatient utilization, 0.99; 95% CI, 0.71-1.39).
No disparities were noted for Blacks using MAC prophylaxis compared to Whites (adjusted
odds ratio without outpatient utilization, 0.87; 95% CI, 0.48-1.57; adjusted odds ratio with
outpatient utilization, 0.90; 95% CI, 0.49-3.03).
Discussion
Based on the studies identified in this literature review, the evidence regarding racial
disparities for the use of OI prophylactic regimens remains inconclusive. The studies vary in
the sources of data used, definitions of a prophylactic regimen, variables included in
regression analyses (if performed at all), and in terms of study duration. However, all of the
studies did evaluate PCP prophylaxis. Other studies have tested the hypothesis that Blacks
with HIV/AIDS use sub-optimal antiretroviral therapy and experience poorer health
outcomes compared to Whites with HIV/AIDS.29-34 However, the evidence to support this
hypothesis remains inconclusive.
One consistent element throughout the majority of studies that documented race-based
disparities was their source of data collection.19,20,22,23 These studies relied only on data
collected from one-on-one interviews and patient questionnaires. It is possible that these
studies introduced recall bias into their results, a bias that has previously noted in HIV
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patients in assessing medication use.35,36 Patients may not have recalled specific clinical
details about medications used whereas medical records and patient charts are typically
completed by trained medical professionals and provide much more detailed information.
For instance, Shapiro et al. instructed patients to provide a range of CD4+ counts if they
could not recall the exact value.22 Monitoring CD4+ count is imperative to assessing when a
patient should be placed on OI prophylaxis.4 A patient-reported range or estimate may skew
the proportion of patients that truly require prophylaxis, which may have influenced some of
their study outcomes.
Another bias with patient interviews is the attitude of distrust held by some Black study
subjects, which may have precluded them from fully engaging in research activities. Black
study participants have been shown to be less trusting of research investigators than White
study participants.37 After surveying Black and White individuals across the United States
regarding their attitudes and reservations for engaging in research activities, Blacks were
more likely to cite reasons for not participating compared to Whites. One reason included
distrust that their physicians would not fully explain the risks associated with participation in
such research. They also did not believe they could freely ask their physician questions.37
Yet another issue involved cultural competency. Cultural competency refers to how one can
effectively interact with individuals of other cultural backgrounds. A survey in Baltimore,
MD was conducted to observe how minority patients rated their physicians’ level of cultural
competency.38 Patients of physicians with greater cultural competency were more likely to
share information with their physicians. Black participants completing interviews may be
negatively influenced if the interviewees or medical professionals are of a non-Black race.
On the contrary, there are data to suggest that patient-provider race concordance has a
negligible impact on minority health. A systematic review of the literature concluded that
the evidence supporting an association between concordant race and health outcomes is in
fact inconclusive.39 Future investigations should strive to identify factors that may influence
the interaction between Black and other minority patients and their healthcare providers.
Of the six studies that did not document racial disparities for PCP prophylaxis, the studies
by Moore et al. and Asch et al. were the only two to evaluate disparities longitudinally by
assessing prophylaxis usage at study entry and at follow-up.25,27 Their findings suggest that
Blacks may be less likely to use prophylaxis when they first enter care, but any perceived
differences may dissipate as they continue to use proper follow-up. Additionally, five of the
six studies incorporated some form of medical record/patient chart abstraction as a method
for data collection.21,24-26,28 This implies that collecting objective, clinical data from
medical records may be a more reliable source of determining the presence of disparities in
prophylaxis rather than gathering subjective data from patient interviews and questionnaires
alone.
Interestingly, the findings from the present literature review differ from the findings a
previous literature review conducted by Palacio et al.40 Most of the studies from their
review did not find ethnic minorities to be disadvantaged in regards to use of OI
prophylaxis. Some of these discrepancies may be explained by the differences in the search
strategy. For example, Palacio et al. did not explicitly include studies that evaluated Black-
White disparities; rather, they evaluated White/non-White disparities. This resulted in five
articles that were excluded from the present review. They also searched the HealthSTAR
database in addition to MEDLINE, whereas the present study only searched the MEDLINE
database. Additionally, their literature search was conducted on October 1, 2001, which
precluded them from identifying two of the articles included in the present review
(published December 2001 and September 2005).27,28
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Limitations of this Literature Review
Some limitations should be considered when interpreting the findings of this literature
review. Despite an attempt to include all relevant studies, some studies may have been
omitted due to the inclusion/exclusion criteria. The review relied on full-text studies that
were published in peer-reviewed journals that are indexed in MEDLINE. Additionally, this
review did not attempt to evaluate the quality of the individual studies. Patient presentation
at entry to care was not evaluated, which may influence eligibility for prophylaxis. Finally,
publication bias may have influenced some authors’ decisions to submit their study results
for publication due to a lack of statistically significant study findings.
Recommendations for Future Research
Further research is needed to determine whether any racial disparities currently exist in the
use of OI prophylaxis. HAART was first made available in 1996.41 The studies discussed in
this review were conducted between 1987 and 2001. Their findings, although mixed, may
not reflect recent changes in HIV/AIDS clinical practice, thereby creating a gap in
knowledge for potential disparities in the past decade.
While many of these studies evaluated “prophylaxis use,” the studies did not delve deeply
into medication-specific information such as patient safety, pharmacokinetics-
pharmacodynamics, and drug-drug interactions. It is possible that not all patients are
compliant with these recommendations for various reasons and may not receive the full
benefits of treatment. Focusing on these issues may provide deeper insight into what has
been previously denoted as use of OI prophylaxis in the literature.
Based on this review, one may conclude that Blacks may not be disadvantaged for
prophylaxis once they receive care. However, patients can only use prophylaxis once they
have sought care, which raises the complex issue of race-based disparities in access to care.
Future studies should assess for prophylaxis disparities in settings where Black and White
HIV/AIDS patients have equal access to care. Such studies should also evaluate disparities
in testing, delays in care, and presentation at entry into care. This would provide further
insight into differences in prophylaxis eligibility by accounting for “late-presenters” who
may require OI treatment rather than prophylaxis. However, it may become increasingly
difficult to study OI-related disparities as HAART continues to reduce the overall incidence
of these infections in the U.S. HIV/AIDS population. Perhaps the question of such
disparities may extend to other populations, such as those in resource-limited settings, where
OIs remain a common occurrence.
Conclusion
The evidence regarding race-based disparities in opportunistic infections is inconclusive.
Blacks may not necessarily be disadvantaged in using prophylactic medications; however,
certain medication-specific issues regarding prophylaxis have not been fully evaluated.
Future research should explore potential disparities in dose, patient safety,
pharmacokinetics-pharmacodynamics, and drug interactions. Such work has the potential to
identify OI prophylactic therapies with the best safety and efficacy profiles for Blacks with
HIV/AIDS, reduce the occurrence of preventable OIs, and improve health outcomes for this
high-risk population.
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Table 1
Prophylaxis to prevent first episode of opportunistic disease in adults and adolescents with HIV







CD4+ < 200 or
oropharyngeal
candidiasis










TMP-SMX 1 DS PO
TIW
-or-
dapsone 50mg PO BID
or 100mg PO QD
-or-
dapsone 50mg
PO QD + pyrimethamine
50mg PO QW +


































Rifampin 600mg PO QD
for 4 months
-or-




-20mg/kg PO QD for 2
months + either rifampin
600mg PO QD for 2
months or rifabutin













PO QD for 4
months
Pyranzinamide 15-
20mg/kg PO QD + either
rifampin 600mg PO
-or-






























TMP-SMX 1 SS PO QD
-or-
dapsone 50mg PO QD +
pyrimethamine 50mg PO





leucovorin 25mg PO QW
-or-
atovaquone 1500mg PO
QD +/− 25mg PO QD +
leucovorin 10mg PO QD
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Rifabutin 300mg PO QD
-or-
azithromycin 1200mg












































QD (influenza A or B)
-or-
rimantadine 100mg PO BID
-or-
amantadine 100mg PO

















TMP-SMX = trimethoprim-sulfamethoxazole; DS = double strength; SS = single strength; PO = by mouth; BID = twice daily; QD = once daily;
TST = tuberculin skin test; BIW = twice weekly; QW = once weekly; TIW = three times weekly; QM = once monthly; IM = intramuscularly
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